OnKure Therapeutics (OKUR) to Release Earnings on Monday

OnKure Therapeutics (NASDAQ:OKUR) will likely be releasing its results before the market opens on Monday, March 9th. Analysts expect OnKure Therapeutics to post earnings of ($1.15) per share for the quarter.

OnKure Therapeutics Stock Performance

Shares of OKUR stock opened at $3.04 on Friday. The stock has a fifty day simple moving average of $2.77 and a two-hundred day simple moving average of $2.84. The firm has a market capitalization of $41.19 million, a PE ratio of -0.63 and a beta of 0.45. OnKure Therapeutics has a 52-week low of $1.70 and a 52-week high of $5.32.

Hedge Funds Weigh In On OnKure Therapeutics

Institutional investors have recently bought and sold shares of the stock. XTX Topco Ltd purchased a new position in OnKure Therapeutics in the second quarter worth about $25,000. Jane Street Group LLC bought a new stake in shares of OnKure Therapeutics in the 4th quarter valued at approximately $56,000. Rangeley Capital LLC purchased a new position in shares of OnKure Therapeutics in the 2nd quarter worth approximately $71,000. Barclays PLC raised its holdings in OnKure Therapeutics by 4,286.8% during the 4th quarter. Barclays PLC now owns 27,242 shares of the company’s stock valued at $79,000 after buying an additional 26,621 shares during the period. Finally, Kotler Kevin bought a new stake in OnKure Therapeutics in the fourth quarter worth $573,000. 90.98% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OnKure Therapeutics in a research note on Monday, December 22nd. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $32.00.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.